AP1976A - Disulfide, sulfide, sulfoxide and sulfone derivatives of cyclic sugars and uses thereof - Google Patents

Disulfide, sulfide, sulfoxide and sulfone derivatives of cyclic sugars and uses thereof

Info

Publication number
AP1976A
AP1976A AP2006003605A AP2006003605A AP1976A AP 1976 A AP1976 A AP 1976A AP 2006003605 A AP2006003605 A AP 2006003605A AP 2006003605 A AP2006003605 A AP 2006003605A AP 1976 A AP1976 A AP 1976A
Authority
AP
ARIPO
Prior art keywords
disulfide
sulfoxide
sulfide
sulfone derivatives
cyclic sugars
Prior art date
Application number
AP2006003605A
Other languages
English (en)
Other versions
AP2006003605A0 (en
Inventor
Moliner Jose Repolles
Perez-Rasilla Eduardo Salas
Coy Francisco Pubill
Original Assignee
Lacer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacer Sa filed Critical Lacer Sa
Publication of AP2006003605A0 publication Critical patent/AP2006003605A0/xx
Application granted granted Critical
Publication of AP1976A publication Critical patent/AP1976A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2006003605A 2003-10-03 2004-09-29 Disulfide, sulfide, sulfoxide and sulfone derivatives of cyclic sugars and uses thereof AP1976A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302368A ES2258365B1 (es) 2003-10-03 2003-10-03 Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
PCT/EP2004/010882 WO2005037842A1 (en) 2003-10-03 2004-09-29 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof

Publications (2)

Publication Number Publication Date
AP2006003605A0 AP2006003605A0 (en) 2006-04-30
AP1976A true AP1976A (en) 2009-03-16

Family

ID=34451643

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003605A AP1976A (en) 2003-10-03 2004-09-29 Disulfide, sulfide, sulfoxide and sulfone derivatives of cyclic sugars and uses thereof

Country Status (34)

Country Link
US (3) US7521571B2 (de)
EP (1) EP1668017B1 (de)
JP (2) JP4809769B2 (de)
KR (1) KR101141683B1 (de)
CN (1) CN1863805B (de)
AP (1) AP1976A (de)
AR (1) AR045962A1 (de)
AT (1) ATE423781T1 (de)
AU (1) AU2004281916B2 (de)
BR (1) BRPI0415020A (de)
CA (1) CA2540500C (de)
DE (2) DE602004019666D1 (de)
DK (1) DK1668017T3 (de)
EA (1) EA008942B1 (de)
EC (1) ECSP066542A (de)
ES (2) ES2258365B1 (de)
GB (1) GB2421241B (de)
GE (1) GEP20084490B (de)
GT (1) GT200400200A (de)
HR (1) HRP20090152T3 (de)
IL (1) IL174371A0 (de)
IS (1) IS8436A (de)
MX (1) MXPA06003610A (de)
NO (1) NO20061872L (de)
NZ (1) NZ546043A (de)
PA (1) PA8614201A1 (de)
PE (1) PE20050436A1 (de)
PL (1) PL1668017T3 (de)
PT (1) PT1668017E (de)
RS (1) RS20060241A (de)
SI (1) SI1668017T1 (de)
UY (1) UY28547A1 (de)
WO (1) WO2005037842A1 (de)
ZA (1) ZA200603475B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
EP1941876A1 (de) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbidmononitrit Derivate zur Behandlung von der Inflammation und okularen Hypertension
ES2332565B1 (es) * 2007-01-23 2010-10-21 Lacer, S.A. Uso de derivados de mononitrato de dianhidrohexita como agentes antiinflamatorios.
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678515A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
IE20070934A1 (en) 2007-12-21 2009-06-24 Trinity College Dublin Efficient aspirin prodrugs
WO2009098113A1 (en) * 2008-02-07 2009-08-13 Nicox S.A. Nitric oxide donor compounds
EP2149576A1 (de) * 2008-07-22 2010-02-03 Lacer, S.A. Isosorbitnitrate mit vasodilatierender Wirksamkeit
EP2149577B1 (de) * 2008-07-22 2011-04-27 Lacer, S.A. Neues stereospezifisches Verfahren zur Herstellung von Dioxabicyclooctan-Verbindungen
EP2177216A1 (de) * 2008-10-13 2010-04-21 Lacer, S.A. Verwendung von Dianhydrohexit-Mononitrat-Derivaten als Heilungsmittel
WO2010055138A1 (en) * 2008-11-14 2010-05-20 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2199294A1 (de) 2008-12-19 2010-06-23 Lacer, S.A. Neues stereoskopisches Verfahren zur Herstellung von Dioxa-Bicyclooctan-Nitratverbindungen
US20130131161A1 (en) * 2009-12-23 2013-05-23 Michael R. Bristow Methods and compositions for cardiovascular diseases and conditions
FR2977252B1 (fr) * 2011-06-30 2013-08-02 Seppic Sa Nouveaux esters de derives n-acyles d'acides amines et d'isosorbide, procede pour leur preparation, et utilisation en cosmetique et comme medicament.
JP6021938B2 (ja) 2011-12-16 2016-11-09 スリーエム イノベイティブ プロパティズ カンパニー メルカプト含有ビスアンヒドロヘキシトール誘導体及びその使用
KR20150123324A (ko) * 2013-03-05 2015-11-03 아처 다니엘 미드랜드 캄파니 이소헥시드 모노트리플레이트 및 이의 합성 방법
CN116173012A (zh) * 2022-12-05 2023-05-30 温州医科大学 白当归脑在制备缺血性脑卒中神经保护用药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290885A2 (de) * 1987-05-08 1988-11-17 CHIESI FARMACEUTICI S.p.A. 1,4:3,6-Dianhydrosorbit-2-mononitrat- und -5-mononitratester, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus
EP0530887A1 (de) * 1991-08-07 1993-03-10 Laboratoires Hoechst S.A. Organische Nitrate, Verfahren zu deren Herstellung und ihre Verwendung in der Behandlung von kardiovaskulären Krankheiten
WO2000020420A1 (es) * 1998-10-07 2000-04-13 Lacer, S.A. Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia disminuida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU465217B2 (en) * 1971-04-29 1975-09-18 American Home Products Corporation Mononitrte esters of 1,4:3, 6-dianhydro-d-glucitol
US3886186A (en) 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
DE3102947A1 (de) 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
US4891373A (en) * 1988-11-23 1990-01-02 Pfizer Inc. Aminopropanol derivatives of 1,4:3,6-dianhydrohexitol nitrates, processes for their preparation and their use as medicaments
ES2125342T3 (es) * 1992-07-30 1999-03-01 Cal Int Ltd Esteres y combinaciones de un nitrato organico y de un salicilato.
DE4410997A1 (de) * 1994-03-30 1995-10-26 Isis Pharma Gmbh Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
IL120531A (en) * 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US20020013483A1 (en) * 2000-07-13 2002-01-31 Consortium Fur Elektrochemische Industrie Gmbh Process for the preparation of dianhydrohexitol bisacylates
EP1337283A4 (de) * 2000-10-27 2005-05-18 Nitromed Inc Verfahren zur behandlung von gefässerkrankungen, die durch stickoxidmangel gekennzeichnet sind
UA63467A (en) 2003-04-22 2004-01-15 Pharmaceutical composition of organic nitrates, dosage form based on pharmaceutical composition of organic nitrates and method of manufacture
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290885A2 (de) * 1987-05-08 1988-11-17 CHIESI FARMACEUTICI S.p.A. 1,4:3,6-Dianhydrosorbit-2-mononitrat- und -5-mononitratester, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen daraus
EP0530887A1 (de) * 1991-08-07 1993-03-10 Laboratoires Hoechst S.A. Organische Nitrate, Verfahren zu deren Herstellung und ihre Verwendung in der Behandlung von kardiovaskulären Krankheiten
WO2000020420A1 (es) * 1998-10-07 2000-04-13 Lacer, S.A. Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia disminuida

Also Published As

Publication number Publication date
CN1863805A (zh) 2006-11-15
US7777058B2 (en) 2010-08-17
DE112004001860T5 (de) 2006-07-27
CA2540500A1 (en) 2005-04-28
GEP20084490B (en) 2008-09-25
GT200400200A (es) 2005-05-23
US8541607B2 (en) 2013-09-24
JP2007507451A (ja) 2007-03-29
CN1863805B (zh) 2010-06-16
RS20060241A (sr) 2008-06-05
US20090169560A1 (en) 2009-07-02
IS8436A (is) 2006-05-03
ZA200603475B (en) 2007-09-26
PT1668017E (pt) 2009-03-09
EP1668017A1 (de) 2006-06-14
EA200600694A1 (ru) 2006-10-27
HRP20090152T3 (en) 2009-05-31
ECSP066542A (es) 2006-10-17
BRPI0415020A (pt) 2006-11-07
EP1668017B1 (de) 2009-02-25
DK1668017T3 (da) 2009-05-11
KR20060066743A (ko) 2006-06-16
UY28547A1 (es) 2005-04-29
MXPA06003610A (es) 2006-06-05
US20100196387A1 (en) 2010-08-05
ES2258365B1 (es) 2007-12-01
ATE423781T1 (de) 2009-03-15
GB2421241A (en) 2006-06-21
WO2005037842A1 (en) 2005-04-28
AP2006003605A0 (en) 2006-04-30
US20060235052A1 (en) 2006-10-19
AU2004281916A1 (en) 2005-04-28
DE602004019666D1 (de) 2009-04-09
HK1092807A1 (en) 2007-02-16
CA2540500C (en) 2012-08-28
US7521571B2 (en) 2009-04-21
AR045962A1 (es) 2005-11-16
EA008942B1 (ru) 2007-10-26
IL174371A0 (en) 2006-08-01
GB2421241B (en) 2008-04-16
NZ546043A (en) 2009-02-28
PE20050436A1 (es) 2005-06-23
PA8614201A1 (es) 2005-05-24
SI1668017T1 (sl) 2009-08-31
PL1668017T3 (pl) 2009-07-31
ES2322468T3 (es) 2009-06-22
GB0605574D0 (en) 2006-04-26
ES2258365A1 (es) 2006-08-16
AU2004281916B2 (en) 2010-10-21
NO20061872L (no) 2006-06-30
JP2011012081A (ja) 2011-01-20
JP4809769B2 (ja) 2011-11-09
KR101141683B1 (ko) 2012-05-07

Similar Documents

Publication Publication Date Title
AP1976A (en) Disulfide, sulfide, sulfoxide and sulfone derivatives of cyclic sugars and uses thereof
DK1919458T3 (da) Syreresistent cysteamin, cystamin og derivater deraf
DK1574452T3 (da) Lukket kapsel med åbnemiddel
ATE556593T1 (de) Herbizide enthaltend substituierte thien-3-yl- sulfonylamino(thio)carbonyltriazolin(thi)one und flurtamone
HUS1600006I1 (hu) Helyettesített tien-3-il-szulfonilamino(tio)karboniltriazolin(ti)on-on és 4-HPPD inhibitorokon alapuló gyomirtó készítmények
EP1953194A4 (de) Polyarylen-sulfid-verbindung
ATE407172T1 (de) Schwefelpellet mit h2s-unterdrückungsmittel
DE602004024386D1 (de) Schwefelhaltige naphthoylimidderivate
NO20053564D0 (no) Bis(3)-alkoksyalkan-2-ol)sulfider, sulfoner og sulfoksider: nye overflateaktive midler.
ATE354566T1 (de) Aromatische sulfone und deren medizinische verwendung
PL379466A1 (pl) Heterocykliczne pochodne metylosulfonu
IL185400A0 (en) Synthesis of (e) -alpha, beta unsaturated sulfides, sulfones, sulfoxides and sulfonamides
EP2046322A4 (de) Aryl-vinyl-sulfide, -sulfone, -sulfoxide und -sulfonamide, derivate davon und therapeutische anwendungen davon
IL168893A (en) Sulfide-containing polythiols
PL376646A1 (pl) Prefabrykowany element budowlany
IL179419A0 (en) Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
ATE412645T1 (de) Substituierte thiophene und deren verwendungen
ITBO20050394A1 (it) Pacchetto per il contenimento di articoli sfusi sbozzato per la realizzazione di tale pacchetto e metodo di piegatura di tale sbozzato
ITMI20020772A0 (it) Meccanismo per ante scorrevoli
AP2022A (en) Pesticidal treatment of stored foodstuffs, chambers, structures and works of art with sulphur compounds
AU2003215665A1 (en) Probucol derivatives
GB0228870D0 (en) Sulphur dioxide release coastings
TW517772U (en) Integral structure of auto-door with capable of overall open function
TW551405U (en) Pivot structure of air gates
ATA17322002A (de) Profilstab, insbesondere sparren- oder sprossenprofil